BioNTech agreed to acquire CureVac for about $1.25 billion in an all-stock deal. Deep Apple Therapeutics reached an agreement with Novo Nordisk to develop and commercialize oral small molecule ...
Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued that the company did not lose compliance oversight in China amid local authorities' ...
Matthew Herper covers medical innovation — both its promise and its perils. Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an ...
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a late-stage oncology bispecific antibody, the drugmaker announced Wednesday. The ...
CRISPR Therapeutics and BioNTech have climbed along with many of their peers over the past week. Both are innovative biotechs with catalysts that could drive their stocks higher in the next few years.
Hosted on MSN
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies
Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the global biopharmaceutical market. The company has taken significant strides in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results